Lab Live | Online Event

Lab Live: Online Event

Join us for Lab Live: Sustainability

Thursday 13 May | 2pm

This online event will highlight some of the leading sustainable practices, products and initiatives within the laboratory industry and give you practical advice on improving the environmental friendliness of your company.

With leading speakers from Greenlight Laboratories, Kimberly-Clark and University College London, this event is one you won’t want to miss.

Stay tuned for the final speaker line-up and session overviews.

Access Lab Live: Collaboration is Key on-demand

Lab Live: Collaboration is Key

The Covid-19 pandemic has called attention to the importance of collaboration across multiple sectors in finding a solution to a seemingly insurmountable problem. The pulling-together of the laboratory community over the last year has highlighted the unwavering dedication and commitment of those in our industry. 

This online event put a spotlight on collaborations which have accelerated the rapid development of new products and innovations to combat the pandemic, and their potential impact on the future of research.

Keynote Speaker

Alicia Chenoweth, Research Associate, Kings College London

Antibody Fc Engineering: Designing Antibodies for Covid-19, Cancer, and Beyond

Speaker Bio: Dr Alicia Chenoweth is a postdoctoral Research Associate in the Cancer Antibody Discovery and Immunotherapy group led by Prof. Sophia Karagiannis at King’s College London. Alicia’s research focuses on IgG antibody engineering to improve immune cell function and recruitment in breast cancer, and is funded by Breast Cancer Now.  Alicia studied her PhD under the supervision of Prof. Mark Hogarth at the Burnet Institute and Monash University in Melbourne, Australia. Her thesis focused on how modifying the Fc region of IgG impacted the interaction with Fc receptors in humans and non-human primates and how this affected inflammatory cell function. Alicia is currently the co-chair for the Antibody Biology and Engineering Gordon Research Seminar, to be held in 2022 in California.

Participating companies

Hosted by

Name

18 March 2pm GMT

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Sameer Savani

Head of Innovation and Engineering at ADS

Programme

Antibody Fc Engineering: Designing Antibodies for Covid-19, Cancer, and Beyond

Thursday 18 March | 2pm GMT

Alicia Chenoweth, Research Associate, Kings College London

Session Outline: Monoclonal antibodies have become one of the most clinical successful therapeutic agents against a range of diseases, including cancer, autoimmune diseases, and most recently SARS-CoV-2. Although engagement of the antigen via the variable Fab portion of the antibody is essential, the function of many therapeutic antibodies also depends, to varying degrees, on the hinge and Fc portion of the antibody and its interaction with receptors on effector cells. Antibody subclass choice is crucial for optimal function and safety of therapeutic antibodies as the functional profile of each subclass differs greatly. Targeted modification of the Fc region and its associated glycan is also a potent and effective approach to tailor the therapeutic function of antibodies for the disease of choice, by improving or reducing the immune cell-associated effector functions and altering the circulating half-life of the antibody. One advantage of these Fc modifications is that they can be easily transferred to antibodies of any target, and so development of novel antibodies, such as those for SARS-CoV-2, have benefited from the modifications previously utilised for different diseases.  

Alicia Chenoweth

Research Associate, Kings College London

Verifying the Efficacy of Disinfecting agents used in food production against SARS-CoV-2

Thursday 18 March | 2pm GMT

Annette Sansom, Microbiologist, Campden BRI Group

Speaker Bio: Annette Sansom joined Campden BRI in 1998 having graduated from the University of Bedfordshire with a BSc in Biology. She is currently a Senior Research Officer in the Safety and Quality group in the Microbiology department at Campden BRI. Annette’s key areas of responsibility include; control of viruses, metagenomic analysis, challenge testing, method validation and antimicrobial testing. Annette also lectures on control of viruses, challenge testing, and food spoilage on the many Microbiology training courses that run at Campden BRI.

Session Outline: It has been well reported that there is no evidence that the SARS-CoV-2 virus is transmitted by foods, however the virus can have a drastic effect on food production and supply. Many reports have indicated that staff working in food production environments can become infected leading to an “outbreak” in a production site and temporary closure of that site. This can have serious implications to a secure food supply chain. Food manufacturers have taken steps to protect their workforce one of which is increased use of sanitising procedures to eliminate the virus. However, these procedures require in-situ verification of efficacy, this cannot be done with the SARS-CoV-2 coronavirus.

A technique has been developed that uses a bacteriophage that is harmless to humans and easy to handle, as a surrogate to SARS-CoV-2 for in-situ disinfectant efficacy tests. Unlike PCR tests that only measure presence of viral RNA, this test measures viral infectivity. In collaborations with disinfectant producers this method has been used in food production sites to verify the efficacy of disinfecting procedures, giving confidence to both manufacturers and their staff that optimum virus removal is operational and helping maintain a secure food supply chain.

Annette Sansom

Microbiologist, Campden BRI Group

Name

18 March 2pm GMT

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Sameer Savani

Head of Innovation and Engineering at ADS

Let's get digital with Lab Innovations 2021

Lab Live: Digital Series

Lab Live: Digital Series

Take a look at upcoming sessions in our digital series. Each session puts a spotlight on a different niche topic in our community from an industry leader.
Find out more

Lab Live Sponsorship

Lab Live Sponsorship

Find out more information on sponsoring a session in our digital series, or sponsor a session in our upcoming online event.
Find out more
Scroll to Top